Last update May 1, 2017

Bacterial Lysates

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Extract of bacterial lysates.

At latest update no published data on excretion into breast milk were found.

It unlikely that it would pass into milk, and, in whatever case, would foreseeably be destroyed in the infant gut.
Moreover, it lacks of toxicity and side effects

There is a controversy on the effectiveness of these products in the prevention or treatment of recurrent respiratory or urinary tract infections.

Alternatives

We do not have alternatives for Bacterial Lysates since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Bacterial Lysates belongs to this group or family:

Tradenames

Main tradenames from several countries containing Bacterial Lysates in its composition:

References

  1. Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frölich R, Dreyer AM, Martin P, Davies T, Fae K, van den Nieuwenhof I, Thoelen S, de Vallière S, Kuhn A, Bernasconi E, Viereck V, Kavvadias T, Kling K, Ryu G, Hülder T, Gröger S, Scheiner D, et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017 Abstract
  2. O'Brien VP, Hannan TJ, Nielsen HV, Hultgren SJ. Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections. Microbiol Spectr. 2016 Abstract
  3. Aydin A, Ahmed K, Zaman I, Khan MS, Dasgupta P. Recurrent urinary tract infections in women. Int Urogynecol J. 2015 Abstract
  4. Mobley HL, Alteri CJ. Development of a Vaccine against Escherichia coli Urinary Tract Infections. Pathogens. 2015 Abstract
  5. Murcia Salud. ¿Existe indicación de vacunas orales para el tratamiento de infecciones urinarias recurrentes? Sumarios de evidencia. 2015 Full text (link to original source) Full text (in our servers)
  6. Tang H, Fang Z, Saborío GP, Xiu Q. Efficacy and Safety of OM-85 in Patients with Chronic Bronchitis and/or Chronic Obstructive Pulmonary Disease. Lung. 2015 Abstract
  7. Pan L, Jiang XG, Guo J, Tian Y, Liu CT. Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. J Clin Pharmacol. 2015 Abstract
  8. Lenk VS, Dorsch B. [Vaccinations in recurrent urinary tract infections--an observation study relating to health economy]. Aktuelle Urol. 2009 Abstract

Total visits

9,541

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM